Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? (Q36119267)

12 August 2017

5 references

18 June 2019

19 September 2019

25 July 2020

30 October 2020

25 January 2021

Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? (English)

1 reference

biomedical investigative technique

12 August 2017

0 references

4 references

18 June 2019

19 September 2019

25 July 2020

30 October 2020

1 reference

PubMed

19 September 2019

schizophrenic psychology

1 reference

25 July 2020

1 reference

30 October 2020

1 reference

25 January 2021

Larry Alphs

1

1 reference

12 August 2017

Fabrizio Benedetti

series ordinal

2

1 reference

12 August 2017

W Wolfgang Fleischhacker

series ordinal

3

1 reference

12 August 2017

John M Kane

series ordinal

4

1 reference

12 August 2017

language of work or name

1 reference

5 January 2012

1 reference

The International Journal of Neuropsychopharmacology

12 August 2017

1 August 2012

5 references

18 June 2019

19 September 2019

25 July 2020

30 October 2020

25 January 2021

6 references

12 August 2017

18 June 2019

19 September 2019

25 July 2020

30 October 2020

25 January 2021

15

1 reference

12 August 2017

7

1 reference

12 August 2017

1003-1014

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Generic

12 August 2017

5 references

18 June 2019

19 September 2019

25 July 2020

30 October 2020

on focus list of Wikimedia project

25 January 2021

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Neurobiological mechanisms of placebo responses

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

New insights into the placebo and nocebo responses

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Mechanisms of placebo and placebo-related effects across diseases and treatments

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

A comprehensive review of the placebo effect: recent advances and current thought

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

When words are painful: unraveling the mechanisms of the nocebo effect

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Control group bias in randomized atypical antipsychotic medication trials for schizophrenia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Placebo or Active Control Trials of Antipsychotic Drugs?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

The ethical basis of psychiatric research: conceptual issues and empirical findings

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

The mechanism of placebo analgesia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Placebo and opioid analgesia-- imaging a shared neuronal network

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Activation of the opioidergic descending pain control system underlies placebo analgesia.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Sources of unreliability in depression ratings

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Early Prediction of Antipsychotic Response in Schizophrenia

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Attitudes of patients with schizophrenia toward placebo-controlled clinical trials.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405769

Trial design issues and treatment effect modeling in multi‐regional schizophrenia trials

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22217384

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22217384

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1017/S1461145711001738

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22217384

1 reference